Submit Search
Upload
Defining a Full Service ADME Data Package
•
Download as PPTX, PDF
•
0 likes
•
132 views
QPS Holdings, LLC
Follow
Defining a Full Service ADME Data Package
Read less
Read more
Health & Medicine
Report
Share
Report
Share
1 of 1
Download now
Recommended
QPS DMPK provides a dedicated team of senior scientists to help select, design and conduct the appropriate ADME studies for your specific compounds and therapeutic targets. Working with QPS DMPK is a collaborative and consultative endeavor that also incorporates our operational effectiveness and dedication to customer service.
QPS DMPK
QPS DMPK
QPS Holdings, LLC
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
QPS Bioanalysis
QPS Bioanalysis
QPS Holdings, LLC
At QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
QPS Biomarkers & Translational Medicine
QPS Biomarkers & Translational Medicine
QPS Holdings, LLC
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
QPS Neuropharmacology
QPS Neuropharmacology
QPS Holdings, LLC
The QPS Bioanalysis General presentation is a summary of our capabilities in Neuropharmacology, Toxicology, DMPK, Bioanalytical, Translational Medicine, and Dermal and Transdermal Preclinical services.
QPS Bioanalysis General
QPS Bioanalysis General
QPS Holdings, LLC
At QPS, CSF Sampling brings together leading-edge technologies and pharmaceutical research and development to reveal pharmacokinetic information about drug concentrations.
QPS CSF Sampling
QPS CSF Sampling
QPS Holdings, LLC
When your focus is Biotherapeutics, QPS’ Global Laboratories provide a full range of bioanalytical solutions to support immunogenicity evaluations during drug development from discovery through clinical development and filing.
QPS Immunogenicity
QPS Immunogenicity
QPS Holdings, LLC
Partnering with QPS for a well-conceived and executed IND-enabling preclinical program will provide you with a detailed assessment of your drug candidate and the most agile, flexible and timely pathway to filing an IND.
QPS IND Enabling Preclinical Studies
QPS IND Enabling Preclinical Studies
QPS Holdings, LLC
Recommended
QPS DMPK provides a dedicated team of senior scientists to help select, design and conduct the appropriate ADME studies for your specific compounds and therapeutic targets. Working with QPS DMPK is a collaborative and consultative endeavor that also incorporates our operational effectiveness and dedication to customer service.
QPS DMPK
QPS DMPK
QPS Holdings, LLC
Whether your focus is on small molecules, proteins, bio-therapeutics, vaccines, or gene therapy, QPS provides a full range of bioanalytical solutions to support drug development from discovery through clinical development and filing.
QPS Bioanalysis
QPS Bioanalysis
QPS Holdings, LLC
At QPS, translational medicine brings together leading-edge technologies and pharmaceutical research and development experience to create a business service unit that works efficiently to advance your drug development program.
QPS Biomarkers & Translational Medicine
QPS Biomarkers & Translational Medicine
QPS Holdings, LLC
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
QPS Neuropharmacology
QPS Neuropharmacology
QPS Holdings, LLC
The QPS Bioanalysis General presentation is a summary of our capabilities in Neuropharmacology, Toxicology, DMPK, Bioanalytical, Translational Medicine, and Dermal and Transdermal Preclinical services.
QPS Bioanalysis General
QPS Bioanalysis General
QPS Holdings, LLC
At QPS, CSF Sampling brings together leading-edge technologies and pharmaceutical research and development to reveal pharmacokinetic information about drug concentrations.
QPS CSF Sampling
QPS CSF Sampling
QPS Holdings, LLC
When your focus is Biotherapeutics, QPS’ Global Laboratories provide a full range of bioanalytical solutions to support immunogenicity evaluations during drug development from discovery through clinical development and filing.
QPS Immunogenicity
QPS Immunogenicity
QPS Holdings, LLC
Partnering with QPS for a well-conceived and executed IND-enabling preclinical program will provide you with a detailed assessment of your drug candidate and the most agile, flexible and timely pathway to filing an IND.
QPS IND Enabling Preclinical Studies
QPS IND Enabling Preclinical Studies
QPS Holdings, LLC
QPS Missouri's Negative Pressure Room. A negative pressure room uses lower air pressure than the rooms surrounding it to allow outside air into the facility. This traps and keeps harmful particles from leaving the potentially contaminated area.
QPS Negative Pressure Room
QPS Negative Pressure Room
QPS Holdings, LLC
A well-conceived and executed preclinical and clinical radiolabeled ADME program will provide you with a detailed assessment of the total fate (mass balance, route, and rate of excretion, tissue distribution, metabolic pathways, and identity and quantity of metabolites) of your drug candidate to support regulatory submissions.
QPS Radiolabeled ADME Studies
QPS Radiolabeled ADME Studies
QPS Holdings, LLC
PK profiling reflects molecular complexity. Since 2001 QPS’ bioanalytical teams have contributed to ADC drug development, supporting the filing of one of the first drug targeting programs and continue to develop customized strategies for novel conjugate molecules.
QPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Holdings, LLC
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
QPS Biomarker Capabilities
QPS Biomarker Capabilities
QPS Holdings, LLC
When your focus is small molecules, biomarkers, or protein biotherapeutics, QPS’ LC-MS/MS laboratories provide a full range of bioanalytical solutions to support drug development from discovery through clinical development.
QPS LC-MS MS of Small & Large Molecules
QPS LC-MS MS of Small & Large Molecules
QPS Holdings, LLC
A timeline of QPS Gene Therapy Milestones
QPS Gene Therapy Milestones
QPS Gene Therapy Milestones
QPS Holdings, LLC
Featured Timeline of QPS Bioanalysis Milestones
QPS Bioanalysis Milestones
QPS Bioanalysis Milestones
QPS Holdings, LLC
This white paper focuses on overcoming the challenges of participating in a pediatric trial. One of the biggest issues is that it is difficult to enroll participants in pediatric trials. Read these 5 strategies to help make it easier to enroll trial participants and complete successful trials.
Overcoming Pediatric Trial Challenges
Overcoming Pediatric Trial Challenges
QPS Holdings, LLC
In recent years, the pharmaceutical industry has witnessed increased political interest and attention due to the increased recognition of the economic importance and financial impact of healthcare as a component of national budgets. Biologic drugs (biologics) have attracted the attention of politicians since biologics have moved out of the niche pharmaceutical arena to contribute 17% of global pharmaceutical sales, representing revenues of more than $120bn in 2009. The market for biologics is growing at twice the rate of pharmaceutical drugs, placing significant cost pressures on government, employers, insurers, and patients. Government and insurers are using several strategies to contain costs but must ensure that the financial burden placed on patients does not restrict access to the health care system. Establishing a regulatory pathway for ‘follow-on’ biologics (biosimilars) was therefore felt to be necessary by many stake holders to encourage competition and reduce prices. Many pharmacutical companies both large and small - are expecting their bottom line growth to be driven by biosimilars and are channeling their R&D budgets to compete in what – according to many - is going to be one of the hottest areas in a radically changing global pharmaceutical market.
Biosimilar Dug Development
Biosimilar Dug Development
QPS Holdings, LLC
"Developing therapies for diseases of the central nervous system (CNS) presents special challenges directly related to the complexity of the human brain and its function of integrating our communications with the outside world. Animal models of human neurological and psychiatric disorders are scarce, because many of these human diseases do not naturally occur in animals, and their study necessitates either specific manipulation (induced models) or the production of genetically modified rodents (transgenic and KO models). Even with these models, it remains unclear, what behavioral domain really resembles higher brain function in humans, and how we can interpret animal data on cognition, emotion, social interaction or activities of daily living. Furthermore, in contrast with other organs, the CNS is sequestered from the general circulation by the blood brain barrier (BBB), potentially preventing many compounds from reaching their intended target. Quantifying how much of and how long a compound resides in the CNS is difficult and indirect. Therefore, the assessment of target engagement calls for specific techniques and know-how. While animal models provide some information as to how well a given compound accesses the brain, this data cannot always be translated directly to humans. Insufficient knowledge of target-compound interaction may be a major cause of failure in drug development for CNS disorders. QPS understands the specific challenges of translation from animal models to human clinical application. Our extensive experience in CNS affords us a clear view of its complexities and its current global clinical study environment. Our direct links with the international scientific community and close relationships with key opinion leaders worldwide, together with our dedicated experts, original strategies and operational transparency, are keys to the effective execution of CNS programs for our clients."
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
QPS Holdings, LLC
The Nobel Prize for the discovery that double-stranded RNAs (dsRNAs) can trigger silencing of complementary messenger RNA sequences was awarded in 1998 and the term ‘RNA interference’ (RNAi) was born, opening the door to a completely novel and untapped market within the pharmaceutical industry. Shortly thereafter, short dsRNAs — or short interfering RNAs (siRNAs) — were generated artificially and used to demonstrate that this process also occurs in mammalian cells. The knowledge that small strands of RNAs can affect gene expression has had a tremendous impact on basic and applied research, and RNAi is currently one of the most promising new approaches for disease therapy. In 2004, only six years after the discovery of RNAi, the first siRNA-based human therapeutics — developed to treat wet age-related macular degeneration — entered phase I clinical trials. RNAi is one of the fastest advancing fields in biology, and the flow of discovery gives true meaning to the expression ‘from the bench to the bedside'.
RNAi Therapeutics
RNAi Therapeutics
QPS Holdings, LLC
Sometimes practical or ethical considerations dictate whether healthy volunteers or patients should be recruited for a particular study. But there are usually sound scientific arguments for collecting PK data from actual patients, to supplement or substitute for PK data obtained from human healthy volunteers during the first phases of drug development. Knowing to what extent the results obtained in healthy volunteers – if available - can be extrapolated to the intended treatment population is critical. The US FDA has recognized the importance of PK studies for determining drug concentration-time profiles in target patient populations.
Pharmacokinetic Studies in Patients
Pharmacokinetic Studies in Patients
QPS Holdings, LLC
This white paper focuses on the 505(b)(2) New Drug Approval (NDA) regulatory pathway, which relies on the public literature of clinical studies and/or the FDA's filing of safety and efficacy data for a previously approved drug.
Seeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA Option
QPS Holdings, LLC
Topical Transdermal Delivery Systems (TDDS) are designed to treat systemic medical conditions or localized joint or muscle conditions using the skin as the route of drug delivery. Whereas dermatologic topical formulations (foams, creams, lotions, ointments, gels, etc.) target skin diseases, Transdermal drug delivery offers important advantages over other routes of administration. It is particularly useful for circumventing liver first-pass metabolism, as an alternative to oral products, for non-invasive localized muscle and joint treatments, to improve and simplify patient compliance, and to allow for discontinuation of drug delivery by removing the patch in the event of adverse drug reactions. TDDS have become successful alternatives for delivering medications to young children, the elderly and the infirm.
Transdermal Delivery Systems
Transdermal Delivery Systems
QPS Holdings, LLC
This white paper focuses on the three key essentials for clinical trials that will support registration of a medicinal product in the EU.
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
QPS Holdings, LLC
ICP-MS detects elements instead of molecules. With the exception of a few elements (C, H, N, O and the noble gases), all elements can be detected. A specific element serves as a tag for the drug molecule of interest, thus enabling quantitation of this drug molecule in a particular matrix. The technique is highly linear and can be used quantitatively for a broad concentration range. Sample processing is relatively easy and throughput times are short, resulting in fast turnaround times.
ICP-MS for Elemental Analysis in Drug Development
ICP-MS for Elemental Analysis in Drug Development
QPS Holdings, LLC
Both ligand binding assays (LBA) and mass spectrometry (MS) methods are widely used in routine bionalysis with expanded applications of MS to large molecules in the years ahead. In this presentation, PK parameters in the rart for three monoclonal antibodies (mAbs) are compared as derived from plasma concentration data as measured by LBA or Immunocapture LC-MS/MS.
Large Molecule Bioanalysis: LC-MS or ELISA? A Case Study
Large Molecule Bioanalysis: LC-MS or ELISA? A Case Study
QPS Holdings, LLC
A well-conceived and executed clinical radiolabelled ADME program will provide you with a detailed assessment of the total fate (mass balance, route and rate of excretion, tissue distribution, metabolic pathways, and identity and quantity of metabolites) of your drug candidate to support regulatory submissions. This presentation explains in 10 steps how we conduct a Human Mass Balance Study at QPS.
QPS Human Mass Balance Presentation
QPS Human Mass Balance Presentation
QPS Holdings, LLC
At QPS Netherlands (QPS-NL), we have expanded our early stage clinical research capabilities in 2012 to include respiratory clinical trials. To this end, QPS-NL is collaborating with Dr. Zuzana Diamant, research pulmonologist and clinical pharmacologist. Professor Diamant has over 20 years of experience in clinical respiratory trials, with a focus on phases 0, I and II proof-of-concept studies in respiratory allergy, asthma and COPD. Zuzana Diamant is Guest Professor at Skane University, Lund, Sweden; collaborating scientist at University Medical Centre Groningen, Dept. of General Practice; and a member of several international scientific networks including the ATS/ERS taskforce for bronchoprovocation testing (allergen challenge) and two editorial boards. Together with our dedicated research physician and epidemiologist Dr. Tjeert Mensinga, our well-trained research team, and onsite laboratory biomarker facilities, this collaboration now enables us to perform consultancy services. These include study design, study set up and the conduct of respiratory POC-studies combining clinical disease models (e.g. inhaled and nasal allergen and LPS challenges) with non-invasive airway samplings (e.g. nasal lavage, nasal brushings, sputum analysis, exhaled airway analysis) to test targeted therapies.
QPS-NL Respiratory Capabilities Presentation
QPS-NL Respiratory Capabilities Presentation
QPS Holdings, LLC
Traditionally, the Netherlands has a major role in the conduct of early stage clinical drug trials. The Netherlands perform well on approval time, quality and expertise; all key drivers for early clinical trial location choice. QPS Netherlands has its own state-of-the-art clinical pharmacology unit (CPU) with 58 beds, an advanced bioanalytical laboratory, radiochemistry laboratory, GMP pharmacy, and a medical recruitment and examination center. The company is strategically located at the University Medical Center Groningen (UMCG). The clinical pharmacology beds and bioanalytical laboratories are highly integrated, resulting in a very efficient operational environment. QPS Netherlands has several strategic partners that further support its operations. Cooperation with these strategic partners gives QPS Netherlands a clear competitive advantage in specific therapeutic fields such as Female Health Care, CNS, Pain and Pulmonary Medicine. Key customers include several global Top 10 pharmaceutical companies and all of the global Top 5 biotechnology companies. Numerous small and medium-sized pharmaceutical and biotechnology companies complete QPS Netherlands’ customer base. Projects at QPS Netherlands range from full-service Phase I/IIa drug development, including strategic consultancy, to dedicated single task projects with high value added.
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
QPS Holdings, LLC
Jason Au University of Waterloo
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Catherine Liao
Lawrence Mulligan Cooper University Hospital
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Catherine Liao
More Related Content
More from QPS Holdings, LLC
QPS Missouri's Negative Pressure Room. A negative pressure room uses lower air pressure than the rooms surrounding it to allow outside air into the facility. This traps and keeps harmful particles from leaving the potentially contaminated area.
QPS Negative Pressure Room
QPS Negative Pressure Room
QPS Holdings, LLC
A well-conceived and executed preclinical and clinical radiolabeled ADME program will provide you with a detailed assessment of the total fate (mass balance, route, and rate of excretion, tissue distribution, metabolic pathways, and identity and quantity of metabolites) of your drug candidate to support regulatory submissions.
QPS Radiolabeled ADME Studies
QPS Radiolabeled ADME Studies
QPS Holdings, LLC
PK profiling reflects molecular complexity. Since 2001 QPS’ bioanalytical teams have contributed to ADC drug development, supporting the filing of one of the first drug targeting programs and continue to develop customized strategies for novel conjugate molecules.
QPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Holdings, LLC
To support research and development in different stages of biopharmaceutical compounds and products, QPS offers biomarker services in different global competence centers using a wide range of technology platforms to support programs in any therapeutic area. QPS biomarker capabilities range from small molecule analysis to whole cell characterization.
QPS Biomarker Capabilities
QPS Biomarker Capabilities
QPS Holdings, LLC
When your focus is small molecules, biomarkers, or protein biotherapeutics, QPS’ LC-MS/MS laboratories provide a full range of bioanalytical solutions to support drug development from discovery through clinical development.
QPS LC-MS MS of Small & Large Molecules
QPS LC-MS MS of Small & Large Molecules
QPS Holdings, LLC
A timeline of QPS Gene Therapy Milestones
QPS Gene Therapy Milestones
QPS Gene Therapy Milestones
QPS Holdings, LLC
Featured Timeline of QPS Bioanalysis Milestones
QPS Bioanalysis Milestones
QPS Bioanalysis Milestones
QPS Holdings, LLC
This white paper focuses on overcoming the challenges of participating in a pediatric trial. One of the biggest issues is that it is difficult to enroll participants in pediatric trials. Read these 5 strategies to help make it easier to enroll trial participants and complete successful trials.
Overcoming Pediatric Trial Challenges
Overcoming Pediatric Trial Challenges
QPS Holdings, LLC
In recent years, the pharmaceutical industry has witnessed increased political interest and attention due to the increased recognition of the economic importance and financial impact of healthcare as a component of national budgets. Biologic drugs (biologics) have attracted the attention of politicians since biologics have moved out of the niche pharmaceutical arena to contribute 17% of global pharmaceutical sales, representing revenues of more than $120bn in 2009. The market for biologics is growing at twice the rate of pharmaceutical drugs, placing significant cost pressures on government, employers, insurers, and patients. Government and insurers are using several strategies to contain costs but must ensure that the financial burden placed on patients does not restrict access to the health care system. Establishing a regulatory pathway for ‘follow-on’ biologics (biosimilars) was therefore felt to be necessary by many stake holders to encourage competition and reduce prices. Many pharmacutical companies both large and small - are expecting their bottom line growth to be driven by biosimilars and are channeling their R&D budgets to compete in what – according to many - is going to be one of the hottest areas in a radically changing global pharmaceutical market.
Biosimilar Dug Development
Biosimilar Dug Development
QPS Holdings, LLC
"Developing therapies for diseases of the central nervous system (CNS) presents special challenges directly related to the complexity of the human brain and its function of integrating our communications with the outside world. Animal models of human neurological and psychiatric disorders are scarce, because many of these human diseases do not naturally occur in animals, and their study necessitates either specific manipulation (induced models) or the production of genetically modified rodents (transgenic and KO models). Even with these models, it remains unclear, what behavioral domain really resembles higher brain function in humans, and how we can interpret animal data on cognition, emotion, social interaction or activities of daily living. Furthermore, in contrast with other organs, the CNS is sequestered from the general circulation by the blood brain barrier (BBB), potentially preventing many compounds from reaching their intended target. Quantifying how much of and how long a compound resides in the CNS is difficult and indirect. Therefore, the assessment of target engagement calls for specific techniques and know-how. While animal models provide some information as to how well a given compound accesses the brain, this data cannot always be translated directly to humans. Insufficient knowledge of target-compound interaction may be a major cause of failure in drug development for CNS disorders. QPS understands the specific challenges of translation from animal models to human clinical application. Our extensive experience in CNS affords us a clear view of its complexities and its current global clinical study environment. Our direct links with the international scientific community and close relationships with key opinion leaders worldwide, together with our dedicated experts, original strategies and operational transparency, are keys to the effective execution of CNS programs for our clients."
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
QPS Holdings, LLC
The Nobel Prize for the discovery that double-stranded RNAs (dsRNAs) can trigger silencing of complementary messenger RNA sequences was awarded in 1998 and the term ‘RNA interference’ (RNAi) was born, opening the door to a completely novel and untapped market within the pharmaceutical industry. Shortly thereafter, short dsRNAs — or short interfering RNAs (siRNAs) — were generated artificially and used to demonstrate that this process also occurs in mammalian cells. The knowledge that small strands of RNAs can affect gene expression has had a tremendous impact on basic and applied research, and RNAi is currently one of the most promising new approaches for disease therapy. In 2004, only six years after the discovery of RNAi, the first siRNA-based human therapeutics — developed to treat wet age-related macular degeneration — entered phase I clinical trials. RNAi is one of the fastest advancing fields in biology, and the flow of discovery gives true meaning to the expression ‘from the bench to the bedside'.
RNAi Therapeutics
RNAi Therapeutics
QPS Holdings, LLC
Sometimes practical or ethical considerations dictate whether healthy volunteers or patients should be recruited for a particular study. But there are usually sound scientific arguments for collecting PK data from actual patients, to supplement or substitute for PK data obtained from human healthy volunteers during the first phases of drug development. Knowing to what extent the results obtained in healthy volunteers – if available - can be extrapolated to the intended treatment population is critical. The US FDA has recognized the importance of PK studies for determining drug concentration-time profiles in target patient populations.
Pharmacokinetic Studies in Patients
Pharmacokinetic Studies in Patients
QPS Holdings, LLC
This white paper focuses on the 505(b)(2) New Drug Approval (NDA) regulatory pathway, which relies on the public literature of clinical studies and/or the FDA's filing of safety and efficacy data for a previously approved drug.
Seeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA Option
QPS Holdings, LLC
Topical Transdermal Delivery Systems (TDDS) are designed to treat systemic medical conditions or localized joint or muscle conditions using the skin as the route of drug delivery. Whereas dermatologic topical formulations (foams, creams, lotions, ointments, gels, etc.) target skin diseases, Transdermal drug delivery offers important advantages over other routes of administration. It is particularly useful for circumventing liver first-pass metabolism, as an alternative to oral products, for non-invasive localized muscle and joint treatments, to improve and simplify patient compliance, and to allow for discontinuation of drug delivery by removing the patch in the event of adverse drug reactions. TDDS have become successful alternatives for delivering medications to young children, the elderly and the infirm.
Transdermal Delivery Systems
Transdermal Delivery Systems
QPS Holdings, LLC
This white paper focuses on the three key essentials for clinical trials that will support registration of a medicinal product in the EU.
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
QPS Holdings, LLC
ICP-MS detects elements instead of molecules. With the exception of a few elements (C, H, N, O and the noble gases), all elements can be detected. A specific element serves as a tag for the drug molecule of interest, thus enabling quantitation of this drug molecule in a particular matrix. The technique is highly linear and can be used quantitatively for a broad concentration range. Sample processing is relatively easy and throughput times are short, resulting in fast turnaround times.
ICP-MS for Elemental Analysis in Drug Development
ICP-MS for Elemental Analysis in Drug Development
QPS Holdings, LLC
Both ligand binding assays (LBA) and mass spectrometry (MS) methods are widely used in routine bionalysis with expanded applications of MS to large molecules in the years ahead. In this presentation, PK parameters in the rart for three monoclonal antibodies (mAbs) are compared as derived from plasma concentration data as measured by LBA or Immunocapture LC-MS/MS.
Large Molecule Bioanalysis: LC-MS or ELISA? A Case Study
Large Molecule Bioanalysis: LC-MS or ELISA? A Case Study
QPS Holdings, LLC
A well-conceived and executed clinical radiolabelled ADME program will provide you with a detailed assessment of the total fate (mass balance, route and rate of excretion, tissue distribution, metabolic pathways, and identity and quantity of metabolites) of your drug candidate to support regulatory submissions. This presentation explains in 10 steps how we conduct a Human Mass Balance Study at QPS.
QPS Human Mass Balance Presentation
QPS Human Mass Balance Presentation
QPS Holdings, LLC
At QPS Netherlands (QPS-NL), we have expanded our early stage clinical research capabilities in 2012 to include respiratory clinical trials. To this end, QPS-NL is collaborating with Dr. Zuzana Diamant, research pulmonologist and clinical pharmacologist. Professor Diamant has over 20 years of experience in clinical respiratory trials, with a focus on phases 0, I and II proof-of-concept studies in respiratory allergy, asthma and COPD. Zuzana Diamant is Guest Professor at Skane University, Lund, Sweden; collaborating scientist at University Medical Centre Groningen, Dept. of General Practice; and a member of several international scientific networks including the ATS/ERS taskforce for bronchoprovocation testing (allergen challenge) and two editorial boards. Together with our dedicated research physician and epidemiologist Dr. Tjeert Mensinga, our well-trained research team, and onsite laboratory biomarker facilities, this collaboration now enables us to perform consultancy services. These include study design, study set up and the conduct of respiratory POC-studies combining clinical disease models (e.g. inhaled and nasal allergen and LPS challenges) with non-invasive airway samplings (e.g. nasal lavage, nasal brushings, sputum analysis, exhaled airway analysis) to test targeted therapies.
QPS-NL Respiratory Capabilities Presentation
QPS-NL Respiratory Capabilities Presentation
QPS Holdings, LLC
Traditionally, the Netherlands has a major role in the conduct of early stage clinical drug trials. The Netherlands perform well on approval time, quality and expertise; all key drivers for early clinical trial location choice. QPS Netherlands has its own state-of-the-art clinical pharmacology unit (CPU) with 58 beds, an advanced bioanalytical laboratory, radiochemistry laboratory, GMP pharmacy, and a medical recruitment and examination center. The company is strategically located at the University Medical Center Groningen (UMCG). The clinical pharmacology beds and bioanalytical laboratories are highly integrated, resulting in a very efficient operational environment. QPS Netherlands has several strategic partners that further support its operations. Cooperation with these strategic partners gives QPS Netherlands a clear competitive advantage in specific therapeutic fields such as Female Health Care, CNS, Pain and Pulmonary Medicine. Key customers include several global Top 10 pharmaceutical companies and all of the global Top 5 biotechnology companies. Numerous small and medium-sized pharmaceutical and biotechnology companies complete QPS Netherlands’ customer base. Projects at QPS Netherlands range from full-service Phase I/IIa drug development, including strategic consultancy, to dedicated single task projects with high value added.
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
QPS Holdings, LLC
More from QPS Holdings, LLC
(20)
QPS Negative Pressure Room
QPS Negative Pressure Room
QPS Radiolabeled ADME Studies
QPS Radiolabeled ADME Studies
QPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Regulated Bioanalysis of Antibody Drug Conjugates
QPS Biomarker Capabilities
QPS Biomarker Capabilities
QPS LC-MS MS of Small & Large Molecules
QPS LC-MS MS of Small & Large Molecules
QPS Gene Therapy Milestones
QPS Gene Therapy Milestones
QPS Bioanalysis Milestones
QPS Bioanalysis Milestones
Overcoming Pediatric Trial Challenges
Overcoming Pediatric Trial Challenges
Biosimilar Dug Development
Biosimilar Dug Development
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
Three Lessons to Help Accelerate Pharmaceutical Breakthroughs for CNS Disorders
RNAi Therapeutics
RNAi Therapeutics
Pharmacokinetic Studies in Patients
Pharmacokinetic Studies in Patients
Seeking Drug Approval via the 505(b)(2) NDA Option
Seeking Drug Approval via the 505(b)(2) NDA Option
Transdermal Delivery Systems
Transdermal Delivery Systems
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
Selecting the Location of a Phase I Clinical Trial Site for EU Registration
ICP-MS for Elemental Analysis in Drug Development
ICP-MS for Elemental Analysis in Drug Development
Large Molecule Bioanalysis: LC-MS or ELISA? A Case Study
Large Molecule Bioanalysis: LC-MS or ELISA? A Case Study
QPS Human Mass Balance Presentation
QPS Human Mass Balance Presentation
QPS-NL Respiratory Capabilities Presentation
QPS-NL Respiratory Capabilities Presentation
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Recently uploaded
Jason Au University of Waterloo
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Catherine Liao
Lawrence Mulligan Cooper University Hospital
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Catherine Liao
Gross Anatomy
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
Dr. Rabia Inam Gandapore
Thoracotomy is the surgical procedure with an incision made to access the pleural space and the contents of the thoracic cavity. Given the structures to be accessed with in the cavity, different incisions have been established to easy the procedure and these incisions qualify the types of thoracotomies to be studied hereunder. PRE OP OPTIMIZATION FOR SPECIFIC FACTORS The outcome of surgical procedures is not measured only by clinical end points but also shorter stays and lower costs. Patients’ discharge is delayed commonly due to inadequate pain relief, infection, arrhythmias, prolonged air leak and debility. Many complications that occur from thoracic operations can be anticipated. An aggressive preoperative work up mitigates morbidity and shortens convalescence. APPROACH CONSIDERATIONS There are about three principles that can guides the choice of the thoracotomy incision to be used I. Adequate exposure must be achieved. The choice of incision is aided by a thorough understanding of the surface anatomy and a comprehensive review of the radiographic images that are obtained preoperatively. II. Chest-wall function and appearance should be preserved to the extent possible. This principle include non-spreading video-assisted thoracoscopic surgery (VATS) procedures, muscle-sparing techniques, avoidance of excessive rib retraction, and rib preservation when possible. III. The third principle is that closure must be meticulous and appropriate. Strict layered closure is the rule for thoracic surgical incisions. Every effort should be made to approximate the individual divided chest-wall muscles in appropriate layers; otherwise, a significant delay in the recovery of range of motion (ROM) may result. Care must be taken to avoid over approximating the ribs and to prevent an override; this will help minimize postoperative pain. POST-OPERATIVE CARE AND MONITORING
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
A lecture discussing the challenge of health misinformation and information ecosystem in public health, how this impacts demand promotion in health, and how this then relates to responding to misinformation and infodemics in health emergencies. Appended with lots of tools, guidance and resources for people who want to do more reading.
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
Tina Purnat
Book trailer of one of the most anticipated and the best book for CEE MD/MS Entrance Examination of Nepal.
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Dr. Aryan (Anish Dhakal)
Pharmacology of Constipation
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
gauripg8
Retinal consideration in cataract surgery ARMD DR VO SCLERAL BUCKLE RD VITRECTOMY LATTICE DEGENERATION
Retinal consideration in cataract surgery
Retinal consideration in cataract surgery
KafrELShiekh University
Factors Affecting child behavior in Pediatric Dentistry, Parenting styles
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
Dr Simran Deepak Vangani
Ram Ramanujan Diabetic Care Associates
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
Catherine Liao
A transition period regarding in vitro medical device (IVD) regulation in the European Union (EU) is upon us. The former IVDD regulations are phasing out and IVDR 2017/746 has already taken its place as the acting regulation for IVD manufacturers but also lab developed tests (LDTs) and health institutions. In our upcoming webcast we will talk about the roles and significance of IVDR and ISO 13485 certification for clinical labs and for Golden Helix as a medical device manufacturer. Join us as we will introduce VarSeq 2.6.1 complete with Dx Mode, which offers the use of VarSeq as CE marked medical device. Even more we will also present strategies to facilitate the transition of Golden Helix customers to operate in accordance with IVDR.
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
Golden Helix
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of cardiac pumping: Learning objectives: 1. Discuss the significance of regulation of cardiac pumping 2. Discuss the concepts of preload and afterload 3. Discuss the mechanism and significance of Frank Starling’s Law 4. Discuss the intrinsic mechanisms of regulation of cardiac pumping 5. Discuss the effects of sympathetic and parasympathetic stimulation on the heart 6. Describe how serum potassium and calcium affect the heart function 7. Discuss the effect of body temperature on the heart function Study Resources: 1. Chapter 9, Guyton and Hall Textbook of Medical Physiology, 14th edition 2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition 3. Chapter 30, Ganong’s Review of Medical Physiology, 26th edition 4. Cardiac Cycle - StatPearls, https://www.ncbi.nlm.nih.gov/books/NBK459327/ 5. Chapter 14, Human Physiology An Integrated Approach, Dee Silverthorn, 8th ed
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
MedicoseAcademics
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol that is rapidly distributed in the body and brain. Ethanol alters many neurochemical systems and has rewarding and addictive properties. It is the oldest recreational drug and likely contributes to more morbidity, mortality, and public health costs than all illicit drugs combined. The 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) integrates alcohol abuse and alcohol dependence into a single disorder called alcohol use disorder (AUD), with mild, moderate, and severe subclassifications (American Psychiatric Association, 2013). In the DSM-5, all types of substance abuse and dependence have been combined into a single substance use disorder (SUD) on a continuum from mild to severe. A diagnosis of AUD requires that at least two of the 11 DSM-5 behaviors be present within a 12-month period (mild AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria). The four main behavioral effects of AUD are impaired control over drinking, negative social consequences, risky use, and altered physiological effects (tolerance, withdrawal). This chapter presents an overview of the prevalence and harmful consequences of AUD in the U.S., the systemic nature of the disease, neurocircuitry and stages of AUD, comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and pharmacotherapies for AUD.
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
Audrey Adji Victor Chang Cardiac Research Institute
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Catherine Liao
主題一:家醫醫療群2.0計畫暨代谢症候群之介绍與分享 講師:陳登旺醫師-元成診所 主題二:DKD患者之簡單有效的胰島素強化治療選擇 講師:林昆德醫師-建工萬川診所 主題三:開啟糖尿病患者早期治療對話框 講師:辛世杰醫師-吉泰內科診所
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
Ks doctor
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
Dr KHALID B.M
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Dr KHALID B.M
Linearity concept of significance, standard deviation, chi square test, students T- test, ANOVA test , pharmaceutical science, statistical analysis, statistical methods, optimization technique, modern pharmaceutics, pharmaceutics, mpharm 1 unit i sem, 1 year m pharm, applications of chi square test, application of standard deviation , pharmacy, method to compare dissolution profile, statistical analysis of dissolution profile, important statical analysis, m. pharmacy, graphical representation of standard deviation, graph of chi square test, graph of T test , graph of ANOVA test ,formulation of t test, formulation of chi square test, formula of standard deviation.
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
KavyasriPuttamreddy
Junli Zuo Ruijin Hospital Shanghai Jiaotong University School of Medicine
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
Catherine Liao
Recently uploaded
(20)
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Arterial health throughout cancer treatment and exercise rehabilitation in wo...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
Temporal, Infratemporal & Pterygopalatine BY Dr.RIG.pptx
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
Why invest into infodemic management in health emergencies
Why invest into infodemic management in health emergencies
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Gauri Gawande(9) Constipation Final.pptx
Gauri Gawande(9) Constipation Final.pptx
Retinal consideration in cataract surgery
Retinal consideration in cataract surgery
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
Compare home pulse pressure components collected directly from home
Compare home pulse pressure components collected directly from home
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
Non-Invasive assessment of arterial stiffness in advanced heart failure patie...
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
Aptopadesha Pramana / Pariksha: The Verbal Testimony
Aptopadesha Pramana / Pariksha: The Verbal Testimony
linearity concept of significance, standard deviation, chi square test, stude...
linearity concept of significance, standard deviation, chi square test, stude...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
"Central Hypertension"‚ in China: Towards the nation-wide use of SphygmoCor t...
Download now